Posted by Michael Wonder on 10 Mar 2017
Nicox resubmits AC-170 (Zerviate) NDA to the U.S. FDA
9 March 2017 - CGMP issues at the API manufacturer have been resolved.
Nicox today announced the resubmission of the new drug application for AC-170, its novel, proprietary, cetirizine eye drop formulation for the treatment of ocular itching associated with allergic conjunctivitis.
The brand name provisionally approved by the U.S. FDA for AC-170 is Zerviate.
